Oncology Drugs
694 FDA-approved drugs
TheraRadar tracks 694 FDA-approved oncology drugs from 276 companies across 70 drug classes, led by Novartis, with 23,085 active clinical trials in the pipeline. Explore recent approvals, top companies, active trials by indication, and drug classes for Oncology.
Oncology Approvals by Year
23
'15
14
'16
27
'17
34
'18
25
'19
35
'20
26
'21
27
'22
32
'23
33
'24
53
'25
11
'26
Recent Oncology Drug Approvals
TRABECTEDIN
TRABECTEDIN
2026-10-01
EVER
BOSUTINIB
BOSUTINIB MONOHYDRATE
2026-06-12
Sun Pharma
VENETOCLAX
VENETOCLAX
2026-05-15
ALEMBIC
VEPPANU
VEPDEGESTRANT
adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negativ...
2026-05-01
RIGEL PHARMS
LIFYORLI (COPACKAGED)
RELACORILANT
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-r...
2026-03-25
CORCEPT THERAP
LOARGYS
PEGZILARGINASE-NBLN
hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency...
2026-02-23
IMMEDICA PHARMA AB
FAVLYXA
FLUOROURACIL
patients with: FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients w...
2026-02-20
AVYXA HOLDINGS
IDELALISIB
IDELALISIB
patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patien...
2026-02-17
NATCO
PI3Kδ
AVOPEF
ETOPOSIDE
refractory testicular cancer in adult patients...
2026-02-13
AVYXA HOLDINGS
Topoisomerase II
VYKOURA
LEUCOVORIN CALCIUM
pernicious anemia and megaloblastic anemia secondary to lack of vitamin B 12 , because of the risk o...
2026-02-03
AVYXA HOLDINGS
Dihydrofolate reductaseThymidylate Synthase
FILKRI
FILGRASTIM-LAHA
2026-01-15
ACCORD BIOPHARMA INC.
BONCRESA
DENOSUMAB-MOBZ
postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporot...
2025-12-19
AMNEAL PHARMS
RANKL
OZILTUS
DENOSUMAB-MOBZ
adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where...
2025-12-19
AMNEAL PHARMS
RANKL
RYBREVANT FASPRO
AMIVANTAMAB AND HYALURONIDASE-LPUJ
adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858...
2025-12-17
Johnson & Johnson
EGFRHyaluronanMET
NILOTINIB
NILOTINIB
2025-12-15
TORRENT
ARMLUPEG
PEGFILGRASTIM-UNNE
the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation...
2025-11-28
Lupin
CSF receptor
HYRNUO
SEVABERTINIB
adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) w...
2025-11-19
Bayer
EGFRERBB2
NILOTINIB HYDROCHLORIDE DIHYDRATE
NILOTINIB HYDROCHLORIDE DIHYDRATE
2025-11-19
HETERO LABS LTD V
POHERDY
PERTUZUMAB-DPZB
2025-11-13
SHANGHAI HENLIUS BIOTECH
KOMZIFTI
ZIFTOMENIB
adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleopho...
2025-11-13
KURA
KMT2AMenin
Showing the 20 most recent of 694 oncology drugs. View all 694 →
Top Oncology Companies
Oncology Active Trials by Indication
23,085 active trials — the forward pipeline, not just approvals.
Solid Tumor (Advanced) 3,712 Non-Hodgkin Lymphoma 1,706 Breast Cancer 1,588 NSCLC 1,551 Colorectal Cancer 1,215 Prostate Cancer 909 AML 711 Multiple Myeloma 710
All competitive landscapes → Oncology Drug Classes
Kinase Inhibitor 43
Alkylating Drug 18
RANK Ligand Inhibitor 17
Leukocyte Growth Factor 17
Nucleoside Metabolic Inhibitor 14
Programmed Death Receptor-1 Blocking Antibody 9
HER2/neu Receptor Antagonist 8
Endoglycosidase 6
Vascular Endothelial Growth Factor Inhibitor 6
Retinoid 6
Oncology at a Glance
- Total Drugs
- 694
- Companies
- 276
- Drug Classes
- 70
- Active Trials
- 23,085
- Latest Approval
- 2026-10-01